1. American Gastroenterological Association Institute Technical Review on Prevention and Treatment of Hepatitis B Virus Reactivation During Immunosuppressive Drug Therapy 
Robert P. Perrillo, Robert Gish, Yngve T. Falck-Ytter 
Gastroenterology 
Volume 148, Issue 1, Pages e3 (January 2015)
DOI: /j.gastro
Copyright © 2015 AGA Institute Terms and Conditions

2. Figure 1
Meta-analysis of antiviral agents versus no prophylaxis across a variety of immunosuppressive regimens. The study by Huang et al26 randomized HBsAg-negative/anti-HBc–positive patients to prophylaxis or therapeutic use of entecavir. The other studies enrolled HBsAg-positive patients only and prophylaxis with lamivudine was compared with deferred treatment. (1.1) The pooled estimates show an 87% relative risk reduction (RRR) of reactivation with prophylaxis (95% CI, 70%–94%). (1.2) The pooled estimates show an 84% RRR (95% CI: 58%–94%) of HBV-associated hepatitis flares.
Gastroenterology  , e3DOI: ( /j.gastro )
Copyright © 2015 AGA Institute Terms and Conditions

3. Figure 2
Pooled baseline risk estimate without prophylaxis of HBVr with rituximab in patients who have recovered from hepatitis B infection (HBsAg negative, anti-HBc positive).
Gastroenterology  , e3DOI: ( /j.gastro )
Copyright © 2015 AGA Institute Terms and Conditions

4. Gastroenterology 2015 148, 221-244. e3DOI: (10. 1053/j. gastro. 2014
Copyright © 2015 AGA Institute Terms and Conditions